Randomisation & Sample Size – Clinical BA Study [Power / Sample Size]

posted by Mike_270 – Australia, 2011-02-01 14:18 (5621 d 14:45 ago) – Posting: # 6527
Views: 8,206

Hi ElMaestro,

We are hoping to show that the nutritional supplement increases the absorption and thus bioavailability of the drug. Clinically this medication is known to have low bioavailability, often leading to low systemic exposure below the therapeutic target in patients and potentially reducing its efficacy. It has been shown that meals (particularly high fat meals) substantially increase the bioavailability, so we are hoping to see this effect with a nutritional supplement.

We are also interested in examining if the different doses of the supplement affect the bioavailability of the drug to a different extent, so that if increased bioavailability is observed, we will be able to make a recommendation of how much supplement is needed to optimise the systemic availability of the drug. Thus we are interested in comparing the AUC's between the reference (drug alone) and the drug + differing doses of the supplement (treatments B - D).

Michael

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
143 visitors (0 registered, 143 guests [including 38 identified bots]).
Forum time: 06:03 CEST (Europe/Vienna)

Scientists often have a naïve faith that
if only they could discover enough facts about a problem,
these facts would somehow arrange themselves
in a compelling and true solution.    Theodosius Dobzhansky

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5